Cleveland BioLabs Inc.

Dr. Gudkov has served as one of the company's directors and as the company's Chief Scientific Officer since the company's inception in June 2003. Prior to 1990, he worked at The National Cancer Research Center in Moscow (USSR) where he led a broad research program focused on virology and cancer drug resistance. In 1990, he reestablished his lab at the University of Illinois at Chicago where he became a tenured faculty member in the Department of Molecular Genetics. His lab concentrated on the development of new functional gene discovery methodologies and the identification of new candidate cancer treatment targets. In 1999, he defined p53 as a major determinant of cancer treatment side effects and suggested this protein as a target for therapeutic suppression. In 2001, Dr. Gudkov moved his laboratory to the Lerner Research Institute at the Cleveland Clinic where he became Chairman of the Department of Molecular Biology and Professor of Biochemistry at Case Western Reserve University. In 2007, Dr. Gudkov accepted the position of Senior VP Basic Science and Chair, Department of Cell Stress Biology at Roswell Park Cancer Institute in Buffalo, NY. Dr. Gudkov is not employed full time by the company, but rather divides time between work for CBLI and for Roswell Park.

Mr. Marhofer joined us as the Controller and General Manager in February 2005 and was subsequently appointed to be the company's Chief Financial Officer in August 2005. He was Corporate Controller of Litehouse Products, Inc. from June 2001 to February 2005. He obtained certifications as a Certified Managerial Accountant and Certified Financial Manager in March 2006. Mr. Marhofer earned his Bachelor of Science in Accounting and Marketing from Miami University in Ohio in 1984, and his Masters in Business Administration in Finance from Akron University in Ohio in 1997, where he was named to the National Honor Society of the Financial Management Association.

Dr. Kurman joined Cleveland BioLabs, Inc. as Chief Medical Officer in January 2008. He has spent over twenty-five years in the oncology drug development field. Dr. Kurman is a board certified medical oncologist who practiced community oncology in New Jersey, where he participated as an investigator in oncology clinical trials sponsored by the Eastern Cooperative Oncology Group (ECOG) and the Memorial Adjunct Staff Oncology Group (MASOG). During his career in the pharmaceutical industry, he has held positions of progressive responsibility at Janssen Research Foundation as Director of Oncology, at Cyotgen Corporation as Senior Director of Research and at U.S. Bioscience as Vice-President for Research. Prior to establishing his consultancy, Dr. Kurman served as Vice-President for Clinical and Scientific Operations for Quintiles? Oncology Therapeutics Division. In his nineteen-year career in the pharmaceutical industry, Dr. Kurman has been involved in the regulatory review or commercial launch of four new oncology products. Dr. Kurman received his bachelor?s degree summa cum laude in biology from Syracuse University and his M.D. degree from Cornell University Medical College. He received his training in internal medicine at the State University of New York ? Upstate Medical Center, and his oncology training at Mt. Sinai Medical Center in New York. Dr. Kurman serves on the scientific advisory boards of several companies as well as serving on the board of Avalon Pharmaceuticals, where he is head of the compensation committee, and of Thallion Pharmaceuticals. Dr. Kurman is also an Adjunct Associate Professor of Epidemiology and Health Promotion in the Master of Clinical Trials Program at New York University and an Adjunct Professor for Pharmaceutical Technology Management at the Wesley J. Howe School of Technology Management of Stevens Institute of Technology.

Dr. Kogan has served as one of the company's directors and as the company's Executive Vice President of Business Development since the company's inception in June 2003 and as Secretary since March 2006. From 2001 to 2004, as Director for Business Development at Integrated Genomics, he was responsible for commercial sales and expansion of the company's capital base. Prior to his tenure in business development, Dr. Kogan worked as a Group Leader/Senior Scientist at Integrated Genomics and ThermoGen, Inc. and as Research Associate at the University of Chicago. Dr. Kogan holds a Ph.D. degree in Molecular Biology from VNII Genetica, as well as an M.S. degree in Biology from Moscow State University and an MBA from the University of Chicago.

Dr. Fort enjoyed 26 years in pharmaceutical industry R&D, first at ER Squibb & Sons, New Brunswick, NJ, then Abbott Laboratories, North Chicago, IL, and TAP Pharmaceuticals, Lake Forest, IL with 1 year at Takeda Chemical Ind., Ltd., Osaka, Japan, before joining Cleveland BioLabs on July 1, 2005. He developed expertise in pre-clinical safety assessment with continually increasing responsibilities. At TAP he was Director of Drug Safety. He holds a Ph.D. in Biochemistry & Molecular Biology from the University of Florida, an MBA from the Lake Forest Graduate School of Management, and is certified in toxicology by the American Board of Toxicology. Throughout his career, and particularly at TAP, he gained exposure to all phases of drug development, and contributed to several successful FDA New Drug Applications (NDA) for marketing approval. At Cleveland BioLabs, Dr. Fort is responsible for all drug development activities including manufacturing active pharmaceutical ingredient and drug product, pre-clinical safety assessment, regulatory affairs, and clinical development.

Ed Venkat, Ph.D. joined Cleveland BioLabs, Inc. as Director of Chemistry, Manufacturing and Controls in 2006. He has over twenty years of experience with demonstrated leadership capability in drug development, operation and management of commercial cGMP manufacturing, process engineering, technology transfer, and regulatory and quality control systems. Dr. Venkat has drug development and manufacturing experience with biological compounds and small molecules in both Big Pharma and small biotech. Before joining CBLI, he worked in numerous research and managerial positions at Merck & Co, Inc. (Rahway, NJ) and as the Director of Process Development for GlobeImmune, Inc. (Louisville, CO). In addition to a B.S. degree in Chemical Engineering, Dr. Venkat holds an M.S. degree in Biochemical Engineering from The Indian Institute of Technology (New Delhi, India), a Ph.D. in Chemical and Biochemical Engineering from Rutgers University (New Brunswick, NJ) and a M.S. degree in Executive Technology Management from Stevens Institute of Technology in Hoboken, NJ.

John Gordon, Ph.D. joined Cleveland BioLabs, Inc. as Director of Clinical Studies in 2006 from Forest Laboratories, Inc. in Jersey City, NJ, where he served as Associate Director of CNS Clinical Development and Medical Affairs. Before this, Dr. Gordon held managerial positions in clinical development with Pharmacia Corporation (Kalamazoo, MI) and Fujisawa Healthcare, Inc. (Deerfield, IL). Earlier in his career, Dr. Gordon served as the Director of Clinical Research with Cancer T reatment Centers of America (Zion, IL) and held professorship in Pharmacology with Loyola University School of Medicine (Maywood, IL), The Chicago Medical School (North Chicago, IL) and The University of Health Sciences (location). He has authored or co-authored 54 peer-reviewed journal articles and numerous abstracts, invited book chapters, software manuals and study manuals and reports. Dr. Gordon holds a B.A. degree in Biology/Chemistry from Rockhurst College and a Ph.D. from The University of Kansas School of Medicine ( both in Kansas City, MO).

Mr. Antal has served as one of the company’s directors since July 2006. From 1996 to 2001, Mr. Antal served as Chief Financial Officer of Experian, and from 2001 to 2002 as Chief Investment Officer. Experian is a leading global provider of consumer and business credit information, direct marketing information services, and integrated customer relationship management processes. He also served on the Board of Directors of First American Real Estate Solutions, an Experian joint venture with First American Financial Corp. Mr. Antal earned a Bachelor of Science degree in Business Administration with an Accounting major from The Ohio State University in 1973. He became a Certified Public Accountant (Ohio) in 1975. Since 2002, Mr. Antal has served as an advisor to the board of directors for Plexus Vaccine, Inc., a biotech company, until it was acquired by SIGA Technologies in 2004. In December 2004, he joined the SIGA board of directors, and also currently serves on the audit and corporate governance committees. From May 2004 to August 2005, he was engaged as the Chief Financial Advisor to the Black Mountain Gold Coffee Co. In July 2005, he joined Pathway Data Inc, a privately held company engaged in consumer credit notification and identity theft assistance services, as its part time Chief Financial Officer.

Dr. Perez has served as one of the company’s directors since July 2006. Dr. Perez is currently the President of Berlex Biosciences, which works to combine biotechnology and pharmaceutical discovery and development technologies to deliver innovative treatments for cardiovascular, cancer and immuno-based disorders. He joined Berlex Biosciences in 1993. Dr. Perez earned his undergraduate degree at Mariano Moreno School, Argentina and graduated from Buenos Aires University Medical School. After completing an internship and residency in internal medicine at Beth Israel Medical Center in New York, Dr. Perez was a Fellow in Rheumatology at New York University-Bellevue Medical Center. He served on the NYU faculty until he was recruited by the University of California at San Francisco Medical School (UCSF) to start the Rosalind Russell Arthritis Center at San Francisco General Hospital under the direction of Dr. Ira Goldstein. Dr. Perez is currently a Professor of Medicine at UCSF.

Preet M. Chaudhary is Professor of Medicine at the University of Pittsburgh Medical School, Deputy Director of Translational Research of the University of Pittsburgh Cancer Institute and Co-Director of the Hematological Malignancies Program of University of Pittsburgh. Dr. Chaudhary is an internationally renowned physician-scientist with research interests in several areas of cancer, including cancer drug resistance, biology of normal and leukemic hematopoeitic stem cells, programmed cell death, cellular signaling, molecularly targeted and biological therapies for leukemias, lymphomas, multiple myeloma and solid tumors, and novel strategies to improve the outcome of stem cell transplantation. Dr. Chaudhary has authored or co-authored numerous scientific publications and book chapters in some of the top scientific journals and holds 5 US patents in the areas of hematopoietic stem cell purification, multi-drug resistance to cancer chemotherapy and NF-?B signaling. Dr. Chaudhary has been the recipient of numerous honors, fellowships and awards form national and international research organizations including the National Institutes of Health, Department of Defense, Cancer Research Fund of the Damon-Runyon Walter-Winchell Foundation, Howard Hughes Medical Institute, Leukemia Research Foundation, March of Dimes Foundation, Childhood Cancer Foundation and the Nearburg Family Foundation.